Deployment is the beginning of the evidence story
Medical AI does not operate in a static environment. Imaging protocols vary, patient populations vary, hardware changes, clinical teams develop new habits and performance can drift. That makes the lifecycle of a system part of its safety case. The regulator’s focus on measurement and evaluation in real-world use is significant because it shifts attention from a one-time clearance narrative toward ongoing monitoring, predefined change control and transparent performance boundaries.
Trust is created by visible limits
A high-performing model can still be unsafe when its limits are unclear. The practical product question is therefore: where does the system work, where does it require escalation and how do users know which is which? Evidence must be legible to clinical teams, not simply stored in a technical file. This includes intended use, input quality constraints, validation population, alert behaviour and a process for responding to new failure modes.
The strategic implication
Teams that treat regulatory work as documentation after the product is built will struggle to scale. The better operating model is to design the evidence system alongside the clinical system: data governance, evaluation plans, human factors, post-market signals and traceability. This does not slow innovation by definition. It determines whether innovation can survive contact with clinical reality.